A Study of BGM0504 Injection in Participants with Obesity or Overweight
Status:
RECRUITING
Trial end date:
2026-03-27
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomized, double-blind, placebo-controlled phase III validation clinical study in Chinese adult non-diabetic overweight or obese Participants. The main purpose is to evaluate the clinical efficacy of BGM0504 injection for 36 weeks of administration as an adjunct to diet, exercise, and behavioral interventions in overweight or obese non-diabetic adults in China for weight management, and to evaluate the clinical efficacy and safety of BGM0504 injection for 52 weeks of administration.
Phase:
PHASE3
Details
Lead Sponsor:
BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd.